What question did this study set out to answer?

To evaluate the effectiveness of KRAS p.G12C inhibitors in treating metastatic colorectal cancer.

March 7, 2026

A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science

Key Points

To evaluate the effectiveness of KRAS p.G12C inhibitors in treating metastatic colorectal cancer.
Conducted a systematic review of available literature
Assessed the efficacy of KRAS-G12C inhibitors
Examined the combination with anti-EGFR therapy
Compared results to historical data on chemotherapy-refractory CRC
Initial data shows promising results for KRAS-G12C inhibitors
Combination therapy with anti-EGFR enhances efficacy
Supports future frontline trials with these new treatments

Abstract

Initial results of KRAS-G12C inhibitors appear highly promising when they are combined with anti-EGFR therapy compared to historical therapeutic agents indicated for patients with chemotherapy-refractory CRC. Encouraging benefits warrant frontline trials with these novel therapeutics.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Jeffrey Mathew Boby

Nosakhare Paul Ilerhunmwuwa

Jame Mathew Benny

Journals

Cancer Investigation

Actions

Institutions

University of Michigan

University of Pittsburgh

Government Medical College

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider